Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Condition(s):Inflammatory Bowel Disease (IBD); Clostridium Difficile Infection (CDI)Last Updated:August 15, 2018Completed